详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Impacts of combining pulsed low dose rate radiotherapy and anti-PD-1 antibody on tumor growth and its mechanism for lung cancer in mice

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Radiat Oncol,Radiat Oncol Key Lab Sic, Chengdu, Peoples R China [2]Chengdu Med Coll, Grad Sch, Chengdu, Peoples R China

出处：

ISSN：

关键词： PLDR anti-PD-1 antibody

语种：

WOS：

中科院(CAS)分区：

出版当年[2025]版：

大类 | 2 区

医学

小类 | 2 区肿瘤学 2 区核医学

最新[2025]版：

大类 | 2 区

医学

小类 | 2 区肿瘤学 2 区核医学

JCR分区：

出版当年[2024]版：

Q1 ONCOLOGY Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

最新[2024]版：

Q1 ONCOLOGY Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

影响因子： 5.3 最新[2024版] 5.6 最新五年平均 5.3 出版当年[2024版] 0 出版当年五年平均 5.3 出版前一年[2024版]

第一作者：

第一作者机构： [1]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med,Dept Radiat Oncol,Radiat Oncol Key Lab Sic, Chengdu, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Impacts of Combining Pulsed Low Dose Rate Radiotherapy (PLDR) and Anti -PD-1 Antibody on Tumor Growth and Its Mechanism for Lung Cancer in Mice [2]Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC [3]Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors [4]Phase Ia study of a humanized anti-PD-1 monoclonal antibody (JS001) in Chinese patients with refractory solid tumors [5]Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. [6]Initial analyses of anti-PD-1 antibody plus chemoradiotherapy in patients with recurrent or metastatic head and neck cancer [7]Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study [8]Safety, Efficacy and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03. [9]Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody [10]Response Evaluation Using Contrast-Enhanced Ultrasound for Unresectable Advanced Hepatocellular Carcinoma Treated With Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy